Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2021; 11(5):2218-2231. doi:10.7150/thno.53056 This issue Cite

Review

Cancer photo-immunotherapy: from bench to bedside

Miao Wang1, Jie Rao1, Meng Wang2, Xiaosong Li3✉, Kaili Liu4, Mark F. Naylor5, Robert E. Nordquist6, Wei R. Chen4✉, Feifan Zhou1✉

1. School of Biomedical Engineering, Hainan University, Haikou, 570228, China
2. College of Physics and Optoelectronic Engineering, Shenzhen University, Shenzhen, 518060, China
3. Department of Oncology, the First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China
4. Stephenson School of Biomedical Engineering, The University of Oklahoma, Norman, OK 73019, USA
5. Baylor Scott & White Healthcare, Waco, Texas 76712, USA
6. Immunophotonics, Inc., 4320 Forest Park Ave., #303 (BAL), St. Louis, MO 63108, USA

✉ Corresponding authors: Xiaosong Li: lixiaosongcom.cn; Wei R. Chen: Wei-R-Chenedu; Feifan Zhou: zhouffedu.cn

Citation:
Wang M, Rao J, Wang M, Li X, Liu K, Naylor MF, Nordquist RE, Chen WR, Zhou F. Cancer photo-immunotherapy: from bench to bedside. Theranostics 2021; 11(5):2218-2231. doi:10.7150/thno.53056. https://www.thno.org/v11p2218.htm
Other styles

File import instruction

Abstract

Graphic abstract

Targeted therapy and immunotherapy in combination is considered the ideal strategy for treating metastatic cancer, as it can eliminate the primary tumors and induce host immunity to control distant metastases. Phototherapy, a promising targeted therapy, eradicates primary tumors using an appropriate dosage of focal light irradiation, while initiating antitumor immune responses through induced immunogenic tumor cell death. Recently, phototherapy has been employed to improve the efficacy of immunotherapies such as chimeric antigen receptor T-cell therapy and immune checkpoint inhibitors. Phototherapy and immunoadjuvant therapy have been used in combination clinically, wherein the induced immunogenic cell death and enhanced antigen presentation synergy, inducing a systemic antitumor immune response to control residual tumor cells at the treatment site and distant metastases. This review summarizes studies on photo-immunotherapy, the combination of phototherapy and immunotherapy, especially focusing on the development and progress of this unique combination from a benchtop project to a promising clinical therapy for metastatic cancer.

Keywords: Cancer, phototherapy, immunotherapy, photo-immunotherapy, combination therapy

Citation styles

APA
Wang, M., Rao, J., Wang, M., Li, X., Liu, K., Naylor, M.F., Nordquist, R.E., Chen, W.R., Zhou, F. (2021). Cancer photo-immunotherapy: from bench to bedside. Theranostics, 11(5), 2218-2231. https://doi.org/10.7150/thno.53056.

ACS
Wang, M.; Rao, J.; Wang, M.; Li, X.; Liu, K.; Naylor, M.F.; Nordquist, R.E.; Chen, W.R.; Zhou, F. Cancer photo-immunotherapy: from bench to bedside. Theranostics 2021, 11 (5), 2218-2231. DOI: 10.7150/thno.53056.

NLM
Wang M, Rao J, Wang M, Li X, Liu K, Naylor MF, Nordquist RE, Chen WR, Zhou F. Cancer photo-immunotherapy: from bench to bedside. Theranostics 2021; 11(5):2218-2231. doi:10.7150/thno.53056. https://www.thno.org/v11p2218.htm

CSE
Wang M, Rao J, Wang M, Li X, Liu K, Naylor MF, Nordquist RE, Chen WR, Zhou F. 2021. Cancer photo-immunotherapy: from bench to bedside. Theranostics. 11(5):2218-2231.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use